NEW YORK (TheStreet) -- CHANGE IN RATINGS
Advance Auto was upgraded at Deutsche Bank to buy from hold. $92 price target. Expectations are low, even though industry trends are improving, Deutsche Bank said.
Bed Bath & Beyond was downgraded at Oppenheimer to hold from buy. Valuation call, based on a $78 price target, Oppenheimer said.
Baidu.com was upgraded at Morgan Stanley to overweight from equal-weight. $144.70 price target. Improved outlook and mobile monetization, Morgan Stanley said.
Cerner was downgraded at Robert Baird to neutral from outperform. Risk/reward is more balanced at current levels, Robert Baird said.
Campbell Soup was upgraded at Credit Suisse to neutral from underperform. $48 price target. Company has a stronger foundation and can achieve its growth targets, Credit Suisse said.
Convergys was downgraded at Citigroup to neutral from buy and given a $21 price target. The turnaround has played out and CVG is more fairly valued, Citi said.
Dupont Fabros was upgraded at Robert Baird to outperform from neutral. $27 price target. Recent weakness in the stock has created a great entry point, Robert Baird said.
Diamond Offshore was downgraded at Williams Financial to hold from buy. $77 price target. Company is seeing higher downtime and utilization, in addition to higher expenses, Williams said.
Emcor was downgraded at DA Davidson to neutral from buy. $45 price target. Stock has made a big run, but earnings expectations are coming down, DA Davidson said.
Facebook was downgraded at Argus Research to hold from buy. Valuation call, as second quarter results are likely not sustainable, Argus said.
Flir Systems was downgraded at Keybanc to hold from buy. Valuation call, as the stock has enjoyed a big run, Keybanc said.
Freescale was downgraded at Oppenheimer to perform from outperform. Upside appears limited, barring an acceleration in the macro recovery, Oppenheimer said.
Global Payments was downgraded at UBS to neutral from buy and given a $49 price target. Growth isn't materializing and visibility is limited, UBS said.
Kennametal was downgraded at J.P. Morgan to neutral.
Lazard was upgraded at UBS to neutral from sell and given a $38 price target. Signs of a turnaround are becoming clear as execution improves, UBS said.
L-3 Communications was upgraded at Bank of America/Merrill Lynch to neutral from outperform. $97 price target. Navigating challenging defense budget backdrop better than expected, BofA/Merrill said.
Methanex was upgraded at UBS to buy from neutral and given a $52 price target, said UBS. Pricing is stabilized and operating rates have improved, UBS said.
Motorola Solutions was downgraded at Argus Research to hold from buy. Enterprise segment continues to underperform, Argus said.
Maxim Integrated was downgraded at UBS to neutral from buy. Reflects a $27 price target given slowdown in high-end smartphone sales, said UBS.
Netgear was downgraded at RBC Capital to underperform from sector perform. $27 price target. Core business appears to be deteriorating, RBC Capital said.
Nidec was upgraded to buy at TheStreet Ratings.
Owens-Illinois was upgraded to buy at TheStreet Ratings.
Pinnacle Entertainment was upgraded at BofA/Merrill to buy from underperform. $30 price target. Divesting Lake Charles has removed multiple overhangs, BofA/Merrill said.
Precision Castparts was downgraded at Deutsche Bank to hold from buy. Price target is $245. Lower metal prices and stagnant organic growth leaves limited upside to price target, Deutsche Bank said.
Pulte was upgraded at Credit Suisse to outperform from neutral. $21 price target. Volatility in the stock creates an attractive buying opportunity, Credit Suisse said.
Qlik Technologies was downgraded at Drexel Hamilton to sell. $24 price target. Company will struggle to achieve full-year earnings targets, Drexel Hamilton said.
Quality Systems was downgraded at Lazard Capital Markets to sell from neutral. $18 price target. Company continues to see lower sales, Lazard Capital Markets said.
Revlon was downgraded at BMO Capital to market perform from outperform. Price target increased to $27. Shares are up 75% on the year and it no longer trades at a favorable discount, BMO Capital said.
Solarwinds was downgraded at Needham to hold from buy. Company missed expectations and has several moving parts with the MSP acquisition, Needham said.
Tesla Motors was upgraded at Deutsche Bank to buy from hold. $160 price target. Capitalizing on inherent advantages of electric vehicles, Deutsche Bank said.
Vantiv was upgraded at UBS to buy and given a $30 price target. Strong visibility and an attractive valuation, said UBS.
Vantiv was downgraded at Wells Fargo to market perform from outperform. Valuation call, as the company is seeing lower sales, Wells Fargo said.
Vertex Pharmaceuticals was downgraded at UBS to neutral and given a $83 price target. Safety concerns about VX-135, UBS said.
VCA Antech upgraded at Piper Jaffray to overweight from neutral. Price target was increased to $32. Favorable industry trends, improving margins, and upcoming buyback programs drive the bull case, Piper Jaffray said.
Zynga was downgraded at Needham to hold from buy. Now expected to generate negative cash flow, Needham said.
Stock Comments / EPS Changes
Arch Capital Group numbers were raised at UBS. Estimates were raised to reflect the second-quarter earnings beat and the expectation of higher loss reserve releases, said UBS. Price target goes to $56.
Biogen Idec numbers were increased at BMO Capital. Estimates were boosted through 2014. Company continues to execute well with Tecfidera, BMO Capital said. Market Perform rating and new $237 price target.
BioMarin estimates were raised at UBS. Reflect the earnings beat, said UBS. Price target is $67.
Bristol-Myers estimates were cut at UBS. Estimates were reduced given the voluntary OTC recalls and investments in the Eliquis launch, said UBS. Price target is $48.
Borg Warner numbers were raised at Citigroup. Estimates were increased given margin expansion and potential for cash deployment, said Citigroup. Price target goes to $106.
Cameron International estimates were cut at UBS. Estimates were reduced given integration delays with OneSubsea, said UBS. Price target is $75.
Chubb Corp. estimates were raised at UBS. Reflect the second-quarter beat and a decrease in the combined ratio outlook, said UBS. Price target is $96.
Celgene estimates, price target were boosted at Cantor Fitzgerald. Shares are now seen reaching $156. Estimates were also upped, as the company raised its guidance, Cantor said. Buy rating.
CME Group numbers were raised at Citigroup. Estimates were increased on better interest rate volatility and capital market activity, said Citigroup. Price target goes to $82.
Dana Holdings estimates were reduced at UBS. Estimates were reduced to reflect fewer share buybacks, said UBS. Price target is $24.
Embraer estimates were reduced at UBS. Estimates were reduced to reflect weaker margin performance and higher R&D expenses, said UBS. Price target is $40.
Gilead Sciences numbers were raised at UBS. Estimates were raised to now include preliminary idelalisib estimates, said UBS. Price target is $72.
General Motors numbers were increased at Citigroup. Estimates were raised on the second-quarter beat, confidence in pickup truck pricing and lower interest expense, said Citigroup. Price target goes to $45.
Hershey estimates, price target were increased at BMO Capital. Estimates were raised through 2014. Higher sales are driving margin expansion, BMO Capital said. Market Perform rating and new $95 price target.
McGraw Hill numbers were raised at UBS. Estimates were raised to reflect the second-quarter beat and higher margins in 2014, said UBS. Price target is now $66.
Maxim Integrated numbers were cut at Citigroup. Estimates were cut on low-quality industrial performance and Samsung retrograde risk, said Citigroup. Price target goes to $27.
Precision Castparts numbers were cut at Citigroup. Estimates were cut to reflect near-term weakness in commercial OE engine demand, said Citi. Price target goes to $266.
Teradyne numbers were lowered at UBS. Future earnings estimates were lowered based on lower growth expectations in the wireless test business, UBS said. Price target was reduced to $20.
T-Mobile numbers were raised at UBS. Estimates were raised as JUMP is now expected to provide an incremental boost to EBITDA, said UBS. Price target is now $28.
WellPoint numbers were raised at UBS. Estimates were raised on a strong quarter and reduced costs, said UBS. The new price target is $87.
>To submit a news tip, email: email@example.com.